The stock of Marker Therapeutics, Inc. (NASDAQ:MRKR) is now priced at $2.07 and the shares are -0.11 points down or -5.05% lower compared to its previous closing price of $2.18. The stock had 174558 contracts set over the past session. MRKR shares’ daily volume is compared to its average trading volume at 562848 shares. However, it has a float of 31.77 million and although its performance was 1.97% over the week, it’s one to watch. MRKR share price recently placing at $2.06 to $2.2. However, some brokerage firms have priced the stock below the average, including one that has called $2.5.
The shorts are running away from the Marker Therapeutics, Inc. stock, with the latest data on short interest released on June 15, 2020, showing that short interest numbers in the MRKR shares have declined. Short interest in the stock represents just 12.48% of its float, but the volume has dropped by -180467. The volume of shorted shares dropped to 3.966 million from 4.146 million shares over the last two weeks. The average intraday trading volume has been 408523 shares, which means that days to cover moved to roughly 9.707901.
In the last trading session, Marker Therapeutics, Inc. (NASDAQ:MRKR) raised by $0.04 over the week and lost -$0.12 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $9.17. The stock recorded its established 52-week high on 07/16/19.
Since 03/13/20, the stock has traded to a low of $1.33 at 55.64%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 1.06. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Marker Therapeutics, Inc.’s two-week RSI is 45.28. This suggests that the stock is neutral at the moment and that MRKR shares’ price movement remains stable. The stochastic readings are equally revealing at 61.26% meaning the MRKR share price is currently in neutral territory.
The technical chart shows that the MRKR stock will likely settle at between $2.16 and $2.25 per share. However, if the stock dips below $2.02, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $1.97.
Currently, the stock is trading in the green of MACD, with a reading of 0.05. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Piper Sandler cut their recommendation for MRKR from Overweight to Neutral in May 12 review while maintai their target price of $5 to $2.50. ROTH Capital analysts see the stock as a Buy with a target price of $ in a flash note released to investors on May 30 initiating covering the stock. Janney analysts see the stock as Buy when the analysts initiated the share price coverage on March 01.
The average rating for the MRKR equity is 1.8 and is currently gathering a bullish momentum. Of 5 analysts tracking Marker Therapeutics, Inc. polled by Reuters, 1 rated MRKR as a hold. The remaining 4 analysts were split evenly. However, the split wasn’t equal as a majority (4) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.